maccura(SZ:300463) Sou Hu Cai Jing·2025-06-23 09:49Core Viewpoint - The company, Maike Biological, is experiencing significant financial challenges, with a notable decline in both revenue and net profit in the latest quarterly report, while its valuation remains high compared to industry averages [1][2]. Company Summary - Maike Biological's stock closed at 11.65 yuan, up 1.57%, with a rolling PE ratio of 235.16 times and a total market capitalization of 7.135 billion yuan [1]. - The company specializes in the research, production, sales, and related services of in vitro diagnostic products, offering a wide range of testing reagents for various medical conditions [1]. - The latest quarterly report for Q1 2025 shows a revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% from the previous year, with a gross margin of 56.76% [2]. Industry Summary - The average PE ratio for the medical device industry is 48.89 times, with a median of 35.79 times, indicating that Maike Biological's valuation is significantly higher than its peers [2]. - The company ranks 118th in terms of PE ratio within its industry, highlighting its relatively high valuation compared to the industry average [1].